Related Experiment Video

Updated: Apr 29, 2026

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

2.4K

The duration of hepatitis B vaccine immunity in pediatric dialysis patients

Rita D Sheth1, Melissa F Peskin, Xianglin L Du

  • 1Department of Pediatrics, Loma Linda University, Coleman Pavilion, 11175 Campus St, Loma Linda, CA, 92356, USA, rsheth@llu.edu.

Pediatric Nephrology (Berlin, Germany)
|May 20, 2014
PubMed

Insights

Hepatitis B immunity wanes quickly in pediatric dialysis patients, especially if vaccinated after starting dialysis. Monitoring antibody titers is crucial for these vulnerable children.

Area of Science:

  • Pediatric Nephrology
  • Immunology
  • Infectious Disease Prevention

Background:

  • Pediatric patients with chronic kidney disease stage 5 on dialysis (CKD 5D) are at high risk for hepatitis B infection.
  • Long-term hepatitis B immunity duration is not well-defined in this population after infant or childhood vaccination.

Purpose of the Study:

  • To determine the duration of hepatitis B immunity in pediatric CKD 5D patients.
  • To assess the impact of dialysis initiation and vaccination timing on hepatitis B immunity.

Main Methods:

  • Retrospective analysis of annual hepatitis B antibody surveillance data from 202 patients.
  • Survival analysis, including Kaplan-Meier and multivariate adjusted analysis, was used to assess immunity duration.

Main Results:

  • Median hepatitis B immunity duration was 106.3 months post-vaccination, but shortened to 37.1 months after dialysis initiation.
  • Vaccination timing significantly impacted immunity duration (p < 0.001).
  • Patients vaccinated after starting dialysis had a 6.13-fold higher risk of losing hepatitis B immunity compared to those vaccinated as infants.

Conclusions:

  • Protective hepatitis B antibody levels decline rapidly after dialysis initiation in pediatric CKD 5D patients.
  • Children vaccinated after starting dialysis experience a more pronounced loss of immunity.
  • Regular monitoring of hepatitis B antibody titers is recommended for all vaccinated pediatric CKD 5D patients.
Abstract

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.6K
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

2.5K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
405
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
409
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
963
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.8K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
552
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271